cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-957Research ArticleОБЗОРЫREVIEWSСовременные принципы терапии фибрилляции предсердий у больных с хронической сердечной недостаточностьюModern principles of atrial fibrillation therapy in patients with chronic heart failureТарзимановаА. И.TarzimanovaA. I.tarzimanova@mail.ruФоминаИ. Г.FominaI. G.tarzimanova@mail.ruВетлужскийА. В.VetluzhskyA. V.tarzimanova@mail.ruСырцоваМ. В.SyrtsovaM. V.tarzimanova@mail.ruМосковская медицинская академия им. И.М.Сеченова на базе ГКБ № 61, МоскваI.M. Sechenov Moscow Medical Academy, City Clinical Hospital No. 61, Moscow20052006200543, ч.II8187Copyright © Тарзиманова А.И., Фомина И.Г., Ветлужский А.В., Сырцова М.В., 20052005Тарзиманова А.И., Фомина И.Г., Ветлужский А.В., Сырцова М.В.Tarzimanova A.I., Fomina I.G., Vetluzhsky A.V., Syrtsova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/957

Обзор посвящен актуальной проблеме современной кардиологии – терапии фибрилляции предсердий (ФП) у больных с хронической сердечной недостаточностью (ХСН). Результаты многоцентровых, клинических исследований свидетельствуют о том, что у пациентов с ХСН ФП встречается значительно чаще, чем у больных без ХСН. Обоснованы алгоритмы выбора оптимальной антиаритмической терапии ФП у больных с ХСН. Обсуждаются возможные стратегии лечения с применением препаратов классов ингибиторов ангиотензин-превращающего фермента и антагонистов рецепторов ангиотензина II.

The review is devoted to an actual problem of modern cardiology – atrial fibrillation (AF) treatment in patients with chronic heart failure (CHF). Multicenter clinical trials demonstrated that CHF patients have AF more often than individuals without CHF. Algorhythms for choosing optimal antiarrhythmic therapy in AF and CHF are proposed. Possible therapeutic strategies, including use of ACE inhibitors and angiotensin II receptor antagonists, are discussed.

фибрилляция предсердийхроническая сердечная недостаточностьтерапияантиаритмические препаратыatrial fibrillationchronic heart diseasetherapyantiarrhythmic drugsReferencesКушаковский М.С. Фибрилляция предсердий. СанктПетербург, ИКФ «Фолиант» 1999; 176с.Кушаковский М.С. Фибрилляция предсердий. СанктПетербург, ИКФ «Фолиант» 1999; 176с.Фомина И.Г., Ветлужский А.В. Существует ли оптимальная стратегия лечения рецидивирующей мерцательной аритмии. Кардиоваск тер профил 2003; 2(3): 70-9.Фомина И.Г., Ветлужский А.В. Существует ли оптимальная стратегия лечения рецидивирующей мерцательной аритмии. Кардиоваск тер профил 2003; 2(3): 70-9.Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1,2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997; 28(6): 1101-6.Feinberg WM, Cornell ES, Nightingale SD, et al. Relationship between prothrombin activation fragment F1,2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke 1997; 28(6): 1101-6.Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-8.Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155(5): 469-73.Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155(5): 469-73.Benjamin EJ, Levy D, Vasiri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-4.Benjamin EJ, Levy D, Vasiri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994; 271(11): 840-4.Naito M, David D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106(2): 284-91.Naito M, David D, Michelson EL, et al. The hemodynamic consequences of cardiac arrhythmias: evaluation of the relative roles of abnormal atrioventricular sequencing, irregularity of ventricular rhythm and atrial fibrillation in a canine model. Am Heart J 1983; 106(2): 284-91.Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69(19): 1570-3.Grogan M, Smith HC, Gersh BJ, Wood DL. Left ventricular dysfunction due to atrial fibrillation in patients initially believed to have idiopathic dilated cardiomyopathy. Am J Cardiol 1992; 69(19): 1570-3.Ricard P, Levy S, Trigano J, et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol 1997; 79(6): 815-6.Ricard P, Levy S, Trigano J, et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol 1997; 79(6): 815-6.Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-66.Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362(9386): 759-66.Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.Vermes E, Tardif J-C, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-31.Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation 2003; 107: 2920-5.Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality. The Framingham Heart Study. Circulation 2003; 107: 2920-5.Brignole М, Menozzi С, Gianfranchi L. Assessment of Atrioventricular Junction Ablation and VVIR Pacemaker Versus Pharmacological Treatment in Patients With Heart Failure and Chronic Atrial Fibrillation. Circulation 1998; 98: 953-60.Brignole М, Menozzi С, Gianfranchi L. Assessment of Atrioventricular Junction Ablation and VVIR Pacemaker Versus Pharmacological Treatment in Patients With Heart Failure and Chronic Atrial Fibrillation. Circulation 1998; 98: 953-60.Deedwania PC, Singh B. Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation. Circulation 1998; 98: 2574-9.Deedwania PC, Singh B. Spontaneous Conversion and Maintenance of Sinus Rhythm by Amiodarone in Patients With Heart Failure and Atrial Fibrillation. Circulation 1998; 98: 2574-9.Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate and rhythm control in patients with recurrent persistent atrial fibrillation. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002; 347: 1825-33.Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate and rhythm control in patients with recurrent persistent atrial fibrillation. The Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. N Engl J Med 2002; 347: 1825-33.Wyse DG. The AFFIRM trial: main trial and substudies – what can we expect? J Interv Cardiac Electrophys 2000; 4: 171-6.Wyse DG. The AFFIRM trial: main trial and substudies – what can we expect? J Interv Cardiac Electrophys 2000; 4: 171-6.Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22: 1852-923.Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation). Eur Heart J 2001; 22: 1852-923.Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92(7): 1954-68.Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 1995; 92(7): 1954-68.Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation – pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-94.Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 2000; 342: 913-20.Roy D, Talajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. N Engl J Med 2000; 342: 913-20.Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 1999; 341: 857-65.Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of arrhythmia and mortality on dofetilide study group. N Engl J Med 1999; 341: 857-65.Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med 1998; 158(3): 229-34.Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke and medical costs. Arch Intern Med 1998; 158(3): 229-34.Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476-84.Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995; 98(5): 476-84.Gosselink AT, Crijns HJ, van den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72(2):161-6.Gosselink AT, Crijns HJ, van den Berg MP, et al. Functional capacity before and after cardioversion of atrial fibrillation: a controlled study. Br Heart J 1994; 72(2):161-6.Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389-96.Kannel WB, Abbott RD, Savage DD, McNamara PM. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983; 106(2): 389-96.Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339(10): 659-66.Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 1998; 339(10): 659-66.Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001; 86: 516-21.Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.Go AS, Hylek EM, Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-5.Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85: 12-9.Reiffel JA. Drug choices in the treatment of atrial fibrillation. Am J Cardiol 2000; 85: 12-9.Brugada P, Andries E. “Tachycardiomyopathy”. The most frequently unrecognized cause of heart failure? Acta Cardiol 1993; 48: 165-9.Brugada P, Andries E. “Tachycardiomyopathy”. The most frequently unrecognized cause of heart failure? Acta Cardiol 1993; 48: 165-9.Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19: 95-106.Fenelon G, Wijns W, Andries E, Brugada P. Tachycardiomyopathy: mechanisms and clinical implications. Pacing Clin Electrophysiol 1996; 19: 95-106.Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 815: 12-25.Yue L, Feng J, Gaspo R, et al. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997; 815: 12-25.Al-Khatib SM, Shaw L, Shah M, et al. Atrial fibrillation in congestive heart failure: Is rhythm control therapy superior to rate control therapy? Program and abstracts of the American Heart Association 2003 Annual Meeting; November 9-12, 2003; Orlando, Florida.Al-Khatib SM, Shaw L, Shah M, et al. Atrial fibrillation in congestive heart failure: Is rhythm control therapy superior to rate control therapy? Program and abstracts of the American Heart Association 2003 Annual Meeting; November 9-12, 2003; Orlando, Florida.Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002; 144: 597-607.Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial. Am Heart J 2002; 144: 597-607.

The authors declare that there are no conflicts of interest present.